LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

CytomX Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

2.03 2.53

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.95

Max

2.15

Galvenie mērījumi

By Trading Economics

Ienākumi

13M

19M

Pārdošana

4.7M

38M

P/E

Sektora vidējais

5.605

56.602

EPS

0.23

Peļņas marža

49.552

Darbinieki

119

EBITDA

14M

18M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+26.05% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 7. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

121M

172M

Iepriekšējā atvēršanas cena

-0.5

Iepriekšējā slēgšanas cena

2.03

Ziņu noskaņojums

By Acuity

55%

45%

319 / 382 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 15. maijs 22:52 UTC

Peļņas
Galvenie tirgus virzītāji

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

2025. g. 15. maijs 20:37 UTC

Top Ziņas
Peļņas

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

2025. g. 16. maijs 00:00 UTC

Tirgus saruna

Xero Bull Stays Positive on Cost Outlook -- Market Talk

2025. g. 15. maijs 23:47 UTC

Tirgus saruna

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

2025. g. 15. maijs 23:38 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 15. maijs 23:38 UTC

Tirgus saruna

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

2025. g. 15. maijs 23:14 UTC

Top Ziņas

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

2025. g. 15. maijs 22:46 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025. g. 15. maijs 22:46 UTC

Iegādes, apvienošanās, pārņemšana

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

2025. g. 15. maijs 22:46 UTC

Iegādes, apvienošanās, pārņemšana

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

2025. g. 15. maijs 22:46 UTC

Iegādes, apvienošanās, pārņemšana

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025. g. 15. maijs 21:58 UTC

Peļņas

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

2025. g. 15. maijs 21:24 UTC

Peļņas

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

2025. g. 15. maijs 20:56 UTC

Tirgus saruna

U.S. Spending Downturn Could Lie Ahead -- Market Talk

2025. g. 15. maijs 20:54 UTC

Tirgus saruna
Peļņas

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

2025. g. 15. maijs 20:54 UTC

Peļņas

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

2025. g. 15. maijs 20:51 UTC

Peļņas

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

2025. g. 15. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 15. maijs 20:50 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

2025. g. 15. maijs 20:50 UTC

Peļņas

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

2025. g. 15. maijs 20:26 UTC

Top Ziņas

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

2025. g. 15. maijs 20:25 UTC

Peļņas

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

26.05% augšup

Prognoze 12 mēnešiem

Vidējais 3 USD  26.05%

Augstākais 3.5 USD

Zemākais 2.5 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

2

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

0.7658 / N/AAtbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Weak Bullish Evidence

Noskaņojums

By Acuity

319 / 382 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.